We have obtained the Certification of Suitability (CEP) for Tiamulin HFU which represents a significant milestone for our company, allowing us to market our product, Tiamulin HFU, across Europe and the USA. With our DMF (Drug Master File) approval attained by May 2023, we are poised to expand our market reach and bring our high-quality pharmaceutical offering to a wider audience.
The Certification of Suitability (CEP) is a recognition of the quality and compliance with European regulations for active pharmaceutical ingredients. This means that our Tiamulin HFU meets the highest standards in terms of safety, efficacy, and quality, thus opening new market opportunities and consolidating our position in the industry.
It is crucial to highlight the importance of this achievement for the entire company: our commitment to excellence has allowed us to reach this milestone, and we must continue to work with determination to continue our growth path. This success is also the result of the dedication and commitment of all of us, so congratulations to everyone for this extraordinary achievement!
